MPTC was the first location in the Eastern United States to offer Varian ProBeam® image-guided intensity-modulated proton therapy and to include pencil-beam scanning in every treatment room. "Our work with Varian has enabled us to reach out beyond the Baltimore–Washington region to maximize the impact of MPTC and its technology," said Katja Langen, PhD, associate chief of proton physics at MPTC and professor of radiation oncology at UMSOM. "Onsite Varian support and collaboration is an essential part of both our clinical and educational programs, and we look forward to expanding our joint training efforts in the near future."

"This dedicated training is part of a larger plan to ensure that MPTC continues to be a world leader in the proton therapy community," said William F. Regine, MD, FACR, FACRO, Isadore and Fannie Schneider Foxman Chair of the UMSOM Department of Radiation Oncology and executive director of MPTC. "By opening these courses to the widest spectrum of U.S. and international participants, we are seeing new collaborative research opportunities and establishing long-term joint efforts. Many physicians who have come to MPTC for these courses and observation periods have sent us their challenging patients to care for while their own centers are being built."


"Education and training remain a vital component in the continued growth of proton therapy around the world," said Moataz Karmalawy, PhD, general manager of Varian's Particle Therapy division. "Partnering with leading institutions like MPTC will allow Varian customers to learn from those that have blazed the proton trail and will help those new programs to build successful proton therapy practices."


About the University of Maryland School of Medicine
Commemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System ("University of Maryland Medicine") has an annual budget of nearly $6 billion and an economic impact in excess of $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu/

Rad Oncology Homepage